In the following video, Motley Fool health-care analyst David Williamson brings investors up to speed on the patent battle between Gilead (NASDAQ:GILD) and Idenix (UNKNOWN:IDIX.DL) over the next generation of drugs to treat hepatitis C, one of the hottest spaces in health care today based on some incredible recent successes. David tells investors how Gilead may have won this particular round of the battle and what the war could mean for both companies down the road.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. It also recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.